Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ul Ain, Qurrat | - |
dc.contributor.author | Chung, Jee Young | - |
dc.contributor.author | Kim, Yong-Hee | - |
dc.date.accessioned | 2022-07-15T23:01:25Z | - |
dc.date.available | 2022-07-15T23:01:25Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157346 | - |
dc.description.abstract | Gene therapy by engineered nucleases is a genetic intervention being investigated for curing the hereditary disorders by targeting selected genes with specific nucleotides for establishment, suppression, abolishment of a function or correction of mutation. Here, we review the fast developing technology of targeted genome engineering using site specific programmable nucleases zinc finger nucleases (ZFNs), transcription activator like nucleases (TALENs) and cluster regulatory interspaced short palindromic repeat/CRISPR associated proteins (CRISPR/Cas) based RNA-guided DNA endonucleases (RGENs) and their different characteristics including pros and cons of genome modifications by these nucleases. We have further discussed different types of delivery methods to induce gene editing, novel development in genetic engineering other than nucleases and future prospects. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.title | Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Hee | - |
dc.identifier.doi | 10.1016/j.jconrel.2014.12.036 | - |
dc.identifier.scopusid | 2-s2.0-84929672850 | - |
dc.identifier.wosid | 000352966200014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.205, pp.120 - 127 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 205 | - |
dc.citation.startPage | 120 | - |
dc.citation.endPage | 127 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ZINC-FINGER NUCLEASES | - |
dc.subject.keywordPlus | STEM-CELL | - |
dc.subject.keywordPlus | EMBRYO MICROINJECTION | - |
dc.subject.keywordPlus | GENE DISRUPTION | - |
dc.subject.keywordPlus | RNA | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | CRISPR | - |
dc.subject.keywordPlus | KNOCKOUT | - |
dc.subject.keywordPlus | CAS9 | - |
dc.subject.keywordPlus | REPAIR | - |
dc.subject.keywordAuthor | Engineered nucleases | - |
dc.subject.keywordAuthor | Genome silencing vs genome editing | - |
dc.subject.keywordAuthor | Gene, protein and cell therapy | - |
dc.subject.keywordAuthor | Viral and non-viral delivery systems | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0168365914008335?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.